{"classes":[{"categories":[{"measurements":[{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG000","lowerLimit":"76.0","upperLimit":"NA","value":"NA"},{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.","groupId":"OG001","lowerLimit":"55.0","upperLimit":"NA","value":"NA"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG002","lowerLimit":"77.0","upperLimit":"NA","value":"253.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG003","lowerLimit":"76.0","upperLimit":"NA","value":"100.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG004","lowerLimit":"170.0","upperLimit":"NA","value":"289.5"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG005","lowerLimit":"100.0","upperLimit":"NA","value":"266.5"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG006","lowerLimit":"424.0","upperLimit":"NA","value":"588.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG007","lowerLimit":"97.0","upperLimit":"NA","value":"200.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG008","lowerLimit":"110.0","upperLimit":"NA","value":"425.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG009","lowerLimit":"128.0","upperLimit":"NA","value":"627.0"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG010","lowerLimit":"46.0","upperLimit":"NA","value":"229.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"6"}],"units":"Participants"}],"description":"Overall survival was defined as the interval between the Baseline visit (Day 1) and the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received INCAGN01876 1.0 milligrams per kilogram (mg/kg) administered intravenously (IV) every 2 weeks (Q2W) in combination with nivolumab 240 mg administered IV Q2W.INCAGN01876 combined with nivolumab.","id":"OG000","title":"Phase 1 Group A: INCAGN01876 1.0 mg/kg Q2W + Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 3.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG001","title":"Phase 1 Group A: INCAGN01876 3.0 mg/kg Q2W + Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 5.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG002","title":"Phase 1 Group A: INCAGN01876 5.0 mg/kg Q2W + Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 10.0 mg/kg administered IV Q2W in combination with nivolumab 240 mg administered IV Q2W.","id":"OG003","title":"Phase 1 Group A: INCAGN01876 10.0 mg/kg Q2W + Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 1.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by nivolumab 240 mg administered IV Q2W starting at Cycle 3.","id":"OG004","title":"Phase 1 Group B: INCAGN01876 1.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 3.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by nivolumab 240 mg administered IV Q2W starting at Cycle 3.","id":"OG005","title":"Phase 1 Group B: INCAGN01876 3.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 5.0 mg/kg administered IV Q2W for a total of 2 doses as run-in, followed by nivolumab 240 mg administered IV Q2W starting at Cycle 3.","id":"OG006","title":"Phase 1 Group B: INCAGN01876 5.0 mg/kg Q2W, Then Nivolumab 240 mg Q2W"},{"description":"Participants received INCAGN01876 1.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV every 6 weeks (Q6W).","id":"OG007","title":"Phase 1 Group C: INCAGN01876 1.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W"},{"description":"Participants received INCAGN01876 3.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.","id":"OG008","title":"Phase 1 Group C: INCAGN01876 3.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W"},{"description":"Participants received INCAGN01876 5.0 mg/kg administered IV Q2W in combination with ipilimumab 1 mg/kg administered IV Q6W.","id":"OG009","title":"Phase 1 Group C: INCAGN01876 5.0 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W"},{"description":"Participants received INCAGN01876 1.0 mg/kg administered IV Q2W in combination with nivolumab 3 mg/kg administered IV Q2W and ipilimumab 1 mg/kg administered IV Q6W.","id":"OG010","title":"Phase 1 Group D: INCAGN01876 + Nivolumab + Ipilimumab"}],"paramType":"MEDIAN","populationDescription":"Phase 1 FAS. Median survival time was estimated using the Kaplan-Meier method. The confidence interval for median survival time was calculated using the method of Brookmeyer and Crowley.","reportingStatus":"POSTED","timeFrame":"up to approximately 44.7 months","title":"Phase 1: Overall Survival","type":"SECONDARY","unitOfMeasure":"Days"}